



Xencor to Present at Upcoming Investor Conferences

August 1, 2019

MONROVIA, Calif.--(BUSINESS WIRE)--Aug. 1, 2019-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune disease, asthma and allergic diseases, today announced that company management will participate in three upcoming conferences:

- **Canaccord Genuity 39th Annual Growth Conference**

Date: Thursday, August 8, 2019

Location: Boston, MA

- **BTIG Biotechnology Conference 2019**

Date: Monday, August 12, 2019

Location: New York, NY

- **2019 Webbush PacGrow Healthcare Conference**

Date: Tuesday, August 13, 2019

Location: New York, NY

Presentation Time: 10:20 a.m. ET

A live webcast of 2019 Webbush PacGrow Healthcare Conference will be available under "Events & Presentations" in the Investors section of the Company's website located at www.xencor.com. A replay of the event will be posted on the Xencor website approximately one hour after the live event and will be available for 30 days following the presentation.

About Xencor, Inc.

Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases. Currently, 14 candidates engineered with Xencor's XmAb[®] technology are in clinical development internally and with partners. Xencor's XmAb antibody engineering technology enables small changes to the structure of monoclonal antibodies resulting in new mechanisms of therapeutic action. For more information, please visit www.xencor.com.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20190801005896/en/>

Source: Xencor, Inc.

Charles Liles
626-737-8118
cliles@xencor.com

Media Contact
Jason I. Spark
Canale Communications
619-849-6005
jason@canalecomm.com